The news: The Drugs Controller General of India (DCGI) granted Bharat Biotech permission on Friday to conduct trials of intranasal booster doses against the coronavirus disease (COVID-19).
- The trials are likely to take place at a variety of beautiful locations.
- Covaxin, an anti-Covid vaccine developed by a Hyderabad-based pharmaceutical company, was recently granted regular market approval for use in the adult population, subject to certain conditions. Covishield from the Serum Institute of India has received a similar nod.
Both widely used vaccines in the country’s pandemic response had previously been restricted to emergency use only.